Cellectar Biosciences, Inc. (CLRB) is a clinical-stage biopharmaceutical company based in Florham Park, New Jersey, developing phospholipid drug conjugate (PDC) therapies for cancer, led by the radiopharmaceutical candidate iopofosine I-131. After a punishing stretch that has left the shares trading near their 52-week low, a cluster of Wall Street price targets still points far above the current quote. The question investors are asking is whether CLRB can reach a $11.50 stock price target.
Four current analyst price targets were reviewed to calculate the central target. Maxim Group and Ladenburg Thalmann each maintain a $10 target with Buy ratings, both most recently updated on August 14, 2026. Roth MKM carries an $11 target (reiterated at Buy in May 2026 after being lowered from $14). Brookline Capital Markets initiated coverage with a $15 target in July 2026. The arithmetic mean of these four figures is $11.50, matching the $11.50 one-year target estimate reported independently by Yahoo Finance and Barron's.
The $10 to $15 range is unusually wide relative to the mean, and the reasoning differs meaningfully. The higher targets emphasize the potential market opportunity for iopofosine I-131 in relapsed or refractory Waldenstrom's macroglobulinemia, a rare B-cell malignancy, while the more cautious figures weigh the execution and financing risk of a pre-revenue company. Notably, several data providers flag that the stock has fallen sharply over the past year and that analyst price targets may not yet have fully adjusted.
With shares around $1.24, the gap to the $11.50 central target implies upside of about 827%, which is a very large move by any standard. The stock's 52-week range of $1.11 to $4.70 underscores how far it has retreated, and the company's market capitalization of roughly $11.7 million sits below the approximately $34 million in cash it reported in its most recent filing.
The path toward the target would depend almost entirely on clinical and regulatory outcomes rather than current fundamentals. Cellectar remains pre-revenue, reporting a net loss of about $22.3 million over the trailing twelve months and diluted EPS (earnings per share) of approximately -$3.46. A re-rating of this magnitude would likely require positive confirmatory data and a credible route toward regulatory approval and commercialization.
The central investment thesis rests on the confirmatory Phase 3 program for iopofosine I-131, which previously received Breakthrough Therapy Designation in Waldenstrom's macroglobulinemia. If the study demonstrates durable response rates consistent with earlier Phase 2 results, it could validate a differentiation argument in an underserved hematologic cancer setting and re-establish a regulatory path toward accelerated approval.
The PDC platform itself provides additional optionality, with earlier-stage programs such as CLR 121125 and CLR 225, along with collaborations with partners including Orano Med and LegoChem Bio. A relatively modest enterprise value relative to reported cash also means any positive clinical catalyst could have an outsized effect on a thinly traded micro-cap stock.
The obstacles are substantial. As a pre-commercial company, Cellectar generates no recurring product revenue, and continued spending on the confirmatory study will consume liquidity. The financing tied to clinical and warrant-related milestones is not assured, and the associated warrant structure creates the risk of meaningful dilution for existing shareholders.
The stock's roughly 61% decline over the past year suggests the market has already discounted significant clinical and regulatory risk. If confirmatory data disappoint, or if the accelerated-approval pathway stalls, the shares could remain under pressure. In that scenario, analyst targets set in mid-2026 may prove optimistic relative to the prevailing stock price.
From a technical standpoint, the shares are trading in the lower portion of a long-term downtrend. The 52-week low near $1.11 represents a key support level, while the $1.28 to $1.31 area has served as recent resistance. More meaningful recovery levels sit well above, with the prior 52-week high of $4.70 marking the most prominent overhead zone. Given the micro-cap float and average volume below 100,000 shares on many sessions, price swings can be pronounced and driven by single news events rather than broad market structure.
Analyst price targets typically reflect a roughly 12-month research horizon, though the timing of individual targets varies here — several were set months ago and may not yet reflect the latest share price. Investors should monitor the confirmatory Phase 3 trial's enrollment and interim data readouts, any regulatory interactions with the FDA (U.S. Food and Drug Administration), financing announcements and dilution, and quarterly cash-burn figures. Analyst revisions following these events will be especially informative, as they will indicate whether the existing price targets remain credible.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive ticker like Cellectar, such tools can help traders discover emerging opportunities, monitor positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how data-driven monitoring can support your trading process.
The $11.50 central target is a calculated average of four analyst price targets, not a guarantee, and it implies an upside of more than 800% from current levels — a very large move that would almost certainly require a decisive clinical or regulatory breakthrough for iopofosine I-131. The bull case rests on confirmatory data and a viable approval pathway in an underserved indication, while the bear case emphasizes pre-revenue status, cash burn, dilution risk, and the possibility that the targets have lagged the stock's collapse. With analysts divided between $10 and $15, investors should treat the target as a reflection of potential outcome, not a forecast, and watch the Phase 3 readout and financing decisions above all else.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with QTTB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then QTTB could also see price increases.
| Ticker / NAME | Correlation To CLRB | 1D Price Change % | ||
|---|---|---|---|---|
| CLRB | 100% | -4.69% | ||
| QTTB - CLRB | 62% Loosely correlated | -0.11% | ||
| ADCT - CLRB | 43% Loosely correlated | -9.58% | ||
| RKTO - CLRB | 42% Loosely correlated | -3.87% | ||
| ANAB - CLRB | 40% Loosely correlated | +0.85% | ||
| VYGR - CLRB | 38% Loosely correlated | -8.29% | ||
More | ||||